LegoChem Biosciences Inc
KOSDAQ:141080
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
89 500
196 100
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
6.8T KRW |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
238.1B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
167.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
83T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.2B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.5B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
276.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.1B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
20B EUR |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
LegoChem Biosciences Inc
Glance View
LegoChem Biosciences Inc., rooted in South Korea, is navigating the complex world of pharmaceutical innovation with a focus sharp enough to captivate both scientists and investors. Founded in 2006, the company has honed its expertise particularly in the field of antibody-drug conjugates (ADCs). This novel approach merges the targeting capabilities of antibodies with the cancer-killing prowess of chemotherapy drugs, aiming to deliver high precision in cancer treatment while minimizing side effects. LegoChem conducts meticulous research and development, advancing its proprietary ConjuAll™ technology platform, which enhances the stability and efficacy of ADCs. This dedication to scientific innovation underscores the company's strategy of robust collaboration and partnerships with global pharmaceutical giants, enabling it to leverage complementary expertise and expedite the commercialization of its cutting-edge therapies. LegoChem Biosciences generates revenue primarily through a strategic business model that revolves around licensing agreements and research collaborations with major pharmaceutical players. The company enters into partnerships where it licenses out its advanced drug discovery platforms, receiving upfront payments, milestones based on developmental progress, and royalties upon successful commercialization of its licensed products. These collaborative strategies not only finance ongoing research but also diversify revenue streams and mitigate the inherent financial risks associated with drug development. By focusing on areas with high unmet medical needs, LegoChem not only positions itself advantageously in the competitive biotech landscape but also aligns with a mission to transform lives through innovation. With a clear-eyed vision and strategic partnerships, LegoChem Biosciences Inc. continues its quest to make significant strides in the realm of targeted cancer therapies.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for LegoChem Biosciences Inc is -29.6%, which is above its 3-year median of -105.3%.
Over the last 3 years, LegoChem Biosciences Inc’s Operating Margin has increased from -35.1% to -29.6%. During this period, it reached a low of -236.7% on Dec 31, 2023 and a high of -8.5% on Mar 31, 2025.